Published on October 20, 2009 at 2:07 AM
OriGene Technologies, Inc. today announced the acquisition of Marligen Biosciences, Inc., a provider of cutting-edge multiplex assays for the Luminex xMAP(R) platform for protein and gene expression profiling assays and testing services, and DNA and RNA purification kits. The acquisition reinforces OriGene's leading position in the bio-medical research industry by expanding the scope of its gene centric toolbox portfolio and further represents another step in OriGene's aggressive growth plan.
The acquisition will enhance OriGene's gene centric product portfolio to include new assay panels and custom assays for drug discovery. Leveraging OriGene's high throughput monoclonal antibody production capability, OriGene intends to complete its development of high quality assay panels and custom assays for researchers that will dramatically hasten and increase efficiencies for drug discovery. OriGene's mammalian cell expressed proteins maintain the most authentic protein structure, post-translational modifications, and functions.
With Marligen's assay development expertise and a strong menu of kits and reagents, and the complementary assets and strengths of OriGene's product line, OriGene will provide a complete product solution to fully address the needs of drug discovery researchers. By acquiring Marligen, OriGene has increased its critical mass and enhanced its competitive strength for creating a gene centric product line which researchers can use to accelerate drug discovery and cellular analysis. All of Marligen's key talent will be retained by OriGene at its new state-of-art research facility in Rockville, Maryland.
SOURCE OriGene Technologies, Inc.